Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniae

被引：29

作者：

Houssaye, S

Gutmann, L

Varon, E

机构：

[1] Hop Europeen Georges Pompidou, CNR Pneumocoques, F-75908 Paris 15, France

[2] Univ Paris 06, INSERM E0004, LRMA, F-75270 Paris, France

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2002年 / 46卷 / 08期

关键词：

D O I：

10.1128/AAC.46.8.2712-2715.2002

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We analyzed the frequencies of selection, the order of acquisition, and the mutations selected on moxifloxacin in two wild-type pneumococcal strains, R6 and 5714. The first selection step showed either a single GyrA mutation or no mutation in any of the quinolone resistance-determining regions. Second-step mutants selected had either a second mutation in ParC or in ParE. Moxifloxacin could belong to these fluoroquinolones, which preferentially target GyrA though probably acting equally through both gyrase and topoisomerase IV.

引用

收藏

页码：2712 / 2715

页数：4

相关论文

共 24 条

[1] Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae:: Contributions of type II topoisomerase mutations and efflux to levels of resistance [J].

Bast, DJ ;

Low, DE ;

Duncan, CL ;

Kilburn, L ;

Mandell, LA ;

Davidson, RJ ;

de Azavedo, JCS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) :3049-3054

[2] Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates [J].

Buxbaum, A ;

Straschil, U ;

Moser, C ;

Graninger, W ;

Georgopoulos, A .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 :13-18

[3] Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada [J].

Chen, DK ;

McGeer, A ;

de Azavedo, JC ;

Low, DE .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) :233-239

[4] The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada -: 1997 results from the SENTRY Antimicrobial Surveillance Program [J].

Doern, GV ;

Pfaller, MA ;

Erwin, ME ;

Brueggemann, AB ;

Jones, RN .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1998, 32 (04) :313-316

[5] Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance [J].

Entenza, JM ;

Que, YA ;

Vouillamoz, J ;

Glauser, MP ;

Moreillon, P .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) :3076-3083

[6] Primary targets of fluoroquinolones in Streptococcus pneumoniae [J].

Fukuda, H ;

Hiramatsu, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :410-412

[7] Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae [J].

Fukuda, H ;

Kishii, R ;

Takei, M ;

Hosaka, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1649-1653

[8] Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae [J].

Gill, MJ ;

Brenwald, NP ;

Wise, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (01) :187-189

[9] Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756 [J].

Hartman-Neumann, S ;

DenBleyker, K ;

Pelosi, LA ;

Lawrence, LE ;

Barrett, JF ;

Dougherty, TJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2865-2870

[10] Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro [J].

Heaton, VJ ;

Ambler, JE ;

Fisher, LM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) :3112-3117